WO2022092041A1 - Composition pour la cavité buccale - Google Patents

Composition pour la cavité buccale Download PDF

Info

Publication number
WO2022092041A1
WO2022092041A1 PCT/JP2021/039363 JP2021039363W WO2022092041A1 WO 2022092041 A1 WO2022092041 A1 WO 2022092041A1 JP 2021039363 W JP2021039363 W JP 2021039363W WO 2022092041 A1 WO2022092041 A1 WO 2022092041A1
Authority
WO
WIPO (PCT)
Prior art keywords
oral
oral composition
component
salt
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2021/039363
Other languages
English (en)
Japanese (ja)
Inventor
一宏 鳥井
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kobayashi Pharmaceutical Co Ltd
Original Assignee
Kobayashi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kobayashi Pharmaceutical Co Ltd filed Critical Kobayashi Pharmaceutical Co Ltd
Publication of WO2022092041A1 publication Critical patent/WO2022092041A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/717—Celluloses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/41—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses

Definitions

  • the present invention relates to an oral composition capable of sterilizing the oral cavity and continuously exerting a moisturizing effect on the oral mucosa.
  • Dry mouth is also called xerostomia, which is a symptom that the amount of saliva secreted decreases and the oral cavity becomes dry.
  • Dry mouth can have various causes such as aging, stress, muscle weakness, diabetes, renal failure, menopausal disorder, side effects of medication, etc., and these causes cannot be completely eliminated, so it is often used for the treatment of dry mouth.
  • Oral sprays, mouthwashes, mouthwashes, artificial saliva, troches and other oral compositions are used to moisturize the oral cavity.
  • Patent Document 1 discloses that an oral composition containing a hydrophobically modified polyether urethane and a wetting agent is effective for the prevention or treatment of dry mouth.
  • Patent Document 2 describes polyglutamate as 0.05 to 5% by mass, an organic acid such as citric acid and a salt thereof, 2 to 6% by mass, l-menthol, glycerin as 10 to 50% by mass, and a surfactant.
  • a composition for oral spray containing 0.01-0.3% by mass of monomentyl succinate is disclosed to be effective in the prevention or treatment of dry mice.
  • the oral composition effective for the prevention or treatment of dry mouth not only imparts a moisturizing effect to the oral cavity but also has a bactericidal effect.
  • an object of the present invention is to provide an oral composition capable of sterilizing the oral cavity and continuously exerting a moisturizing effect on the oral mucosa.
  • the present inventor has found that by using a quaternary ammonium salt and hypromellose in combination in an oral composition, a bactericidal effect is exhibited and synergistic of these components. It was found that the action dramatically improves the sustainability of the moisturizing effect on the oral mucosa.
  • the present invention has been completed by further studies based on such findings.
  • Item 1 An oral composition containing (A) a quaternary ammonium salt and (B) hypromellose.
  • Item 2. The oral composition according to Item 1, further comprising (C) azulene sulfonic acid and / or a salt thereof.
  • Item 3. Item 2. The oral composition according to Item 1 or 2, wherein the component (A) is at least one selected from the group consisting of cetylpyridinium chloride, benzethonium chloride, and benzalkonium chloride.
  • Item 4. Item 6. The oral composition according to any one of Items 1 to 3, which is used for the prevention or treatment of dry mouth.
  • the oral composition of the present invention is effective for oral care because it can continuously exert a moisturizing effect on the oral mucosa while exhibiting a bactericidal effect, and can be suitably used for, for example, prevention or treatment of dry mouth.
  • the oral composition of the present invention is characterized by containing (A) a quaternary ammonium salt and (B) hypromellose.
  • A a quaternary ammonium salt
  • B hypromellose
  • the oral composition of the present invention contains a quaternary ammonium salt (sometimes referred to as component (A)).
  • a quaternary ammonium salt sometimes referred to as component (A)
  • component (A) By containing the quaternary ammonium salt in the external composition of the present invention, it becomes possible to exert a bactericidal effect in the oral cavity.
  • the type of the quaternary ammonium salt is not particularly limited as long as it is pharmaceutically acceptable, but for example, a quaternary ammonium salt having a bactericidal action can be preferably used.
  • a quaternary ammonium salt having a bactericidal action include cetylpyridinium chloride, benzethonium chloride, benzalkonium chloride, decalinium chloride, alkyldimethylammonium chloride, alkyltrimethylammonium chloride, methylbenzethonium chloride, and lauroylcolaminoformyl chloride. Examples thereof include methylpyridinium.
  • the quaternary ammonium salt may be in the form of a solvate such as a hydrate.
  • quaternary ammonium salts may be used alone or in combination of two or more.
  • cetylpyridinium chloride, benzethonium chloride, benzalkonium chloride, and more preferably cetylpyridinium chloride are mentioned.
  • cetylpyridinium chloride, benzethonium chloride, benzalkonium chloride, and more preferably cetylpyridinium chloride are preferable from the viewpoint of further improving the sustainability of the moisturizing effect on the oral mucosa.
  • one component from the quaternary ammonium salt may be used alone, or two or more components may be used in combination.
  • the content of the component (A) in the oral composition of the present invention may be appropriately set according to the type of the component (A) to be used, the formulation form of the oral composition, etc., and may be appropriately set, for example, 0.001. It is about 5% by weight, preferably 0.01 to 2% by weight, and more preferably 0.05 to 1.25% by weight.
  • the oral composition of the present invention contains hypromellose (sometimes referred to as component (B)) in addition to the component (A).
  • hypromellose sometimes referred to as component (B)
  • component (A) in combination with hypromellose, it becomes possible to dramatically improve the sustainability of the moisturizing effect on the oral mucosa by these synergistic actions.
  • Hypromellose is a known cellulose derivative also called hydroxypropylmethyl cellulose.
  • the content of the component (B) in the oral composition of the present invention may be appropriately set according to the formulation form of the oral composition and the like, and is, for example, 0.01 to 1.5% by weight, preferably 0.01 to 1.5% by weight. 0.1 to 1.5% by weight, more preferably 0.2 to 1.5% by weight, still more preferably 0.6 to 1.5% by weight.
  • the sustainability of the moisturizing effect on the oral mucosa can be dramatically improved without causing a decrease in usability due to an increase in viscosity.
  • the ratio of the component (A) to the component (B) is determined according to the content of each of these components.
  • the component is 0.1 to 20 parts by weight, preferably 0.5 to 6 parts by weight, more preferably 1 to 6 parts by weight, still more preferably 2 to 6 parts by weight.
  • the oral composition of the present invention may contain azulene sulfonic acid and / or a salt thereof (sometimes referred to as component (C)) in addition to the components (A) and (B).
  • azulene sulfonic acid and / or a salt thereof sometimes referred to as component (C)
  • the sustainability of the moisturizing effect on the oral mucosa is further improved while exhibiting both the anti-inflammatory effect and the bactericidal effect in the oral cavity. Will be possible.
  • Azulene sulfonic acid is a known anti-inflammatory component also called 1,4-dimethyl-7-isopropylazulene-3-sulfonic acid.
  • the type of salt of azulene sulfonic acid is not particularly limited as long as it is pharmaceutically acceptable, but for example, alkali metal salts such as sodium salt and potassium salt; alkaline earth metal salts such as calcium salt and magnesium salt.
  • Other metal salts such as aluminum salts; Ammonium salts; Acetate, trifluoroacetate, butyrate, palmitate, stearate, fumarate, maleate, succinate, malonate, lactate , Tartrate, citrate and other carboxylates; methanesulfonate, toluenesulfonate, tosylate and other organic sulfonates; methylamine salt, triethylamine salt, triethanolamine salt, morpholine salt, piperazine salt , Pyrrolidine salt, tripyridine salt, picolin salt and other organic amine salts; examples thereof include hydrochlorides, sulfates, nitrates, hydrobromide salts, and inorganic acid salts such
  • a salt of azulene sulfonic acid is preferable, and sodium azulene sulfonic acid is more preferable, from the viewpoint of further improving the sustainability of the moisturizing effect on the oral mucosa.
  • component (C) one component from azulene sulfonic acid and a salt thereof may be used alone, or two or more components may be used in combination.
  • the content thereof may be appropriately set according to the type of the component (C) to be used, the formulation form of the oral composition, and the like. For example, 0.0001 to 5% by weight, preferably 0.001 to 1% by weight, and more preferably 0.01 to 0.5% by weight can be mentioned.
  • the ratio of the component (A) to the component (C) is determined according to the content of both components, for example, (A).
  • the component (B) are 0.01 to 10 parts by weight, preferably 0.01 to 1 part by weight, and more preferably 0.02 to 0.2 parts by weight per 1 part by weight of the component.
  • the oral composition of the present invention may contain a monohydric lower alcohol (sometimes referred to as a component (D)) in addition to the above-mentioned components (A) and (B).
  • a monohydric lower alcohol refers to a monohydric alcohol having 1 to 5 carbon atoms.
  • the type of monohydric lower alcohol is not particularly limited as long as it is pharmaceutically acceptable, but for example, ethanol, n-propanol, isopropanol, n-butanol, sec-butanol, tert-butanol, n-amyl alcohol. , Se-amyl alcohol, isoamyl alcohol, tert-amyl alcohol, neopentyl alcohol and the like. These monohydric lower alcohols may be used alone or in combination of two or more.
  • ethanol is preferable.
  • the content thereof is not particularly limited, but is, for example, 0.01 to 10% by weight, preferably 0.1 to 5% by weight, more preferably. Is 0.5 to 3% by weight.
  • the oral composition of the present invention may contain a polyhydric alcohol (sometimes referred to as a component (E)) in addition to the components (A) and (B) described above.
  • a polyhydric alcohol sometimes referred to as a component (E)
  • polyhydric alcohol is not particularly limited as long as it is pharmaceutically acceptable, but for example, 1,3-butylene glycol, ethylene glycol, propylene glycol, isoprene glycol, diethylene glycol, dipropylene glycol, polyethylene glycol and the like.
  • a dihydric alcohol is preferable, and propylene glycol is more preferable.
  • the content thereof is not particularly limited, but is, for example, 1 to 80% by weight, preferably 10 to 75% by weight, and more preferably 30 to 70% by weight. Weight% is mentioned.
  • the oral composition of the present invention may contain water as part of the base.
  • the content thereof may be appropriately set according to the form of the formulation and the like, but is, for example, 1 to 90% by weight, preferably 10 to 70% by weight. It is preferably 25 to 60% by weight.
  • the oral composition of the present invention may contain other medicinal ingredients in addition to the above-mentioned ingredients, if necessary.
  • Such medicinal ingredients are not particularly limited as long as they can be blended in pharmaceutical products, oral care products, etc., but for example, iodine-based bactericidal ingredients (for example, iodine, povidone iodine, nonoxinol iodine and phenoxy iodine).
  • bronchial dilators include bronchial dilators, antitussives, expectorants, anti-inflammatory agents (other than azulene sulfonic acid and its salts), glucosyltransferase inhibitors, plaque inhibitors, hypersensitivity inhibitors, tooth stone preventives, antipyretic analgesics, antihistamines
  • bronchial dilators include medicines, bactericides (other than quaternary ammonium salts), gastromucosal protective medicines, caffeines, vitamin medicines, Chinese herbs, and raw medicine ingredients.
  • the oral composition of the present invention may contain a base or an additive in order to obtain a desired pharmaceutical form.
  • bases and additives are not particularly limited as long as they can be blended in pharmaceuticals, oral care products, etc., but for example, oily components, surfactants, preservatives, thickeners (other than hypromellose). ), Fragrances, flavoring agents, cooling agents, pigments, deodorants, pigments, buffers, pH adjusters and the like.
  • the shape of the oral composition of the present invention is not particularly limited and may be liquid, solid, semi-solid (gel, ointment, paste) or the like, but liquid is preferable. Be done.
  • the formulation form of the oral composition of the present invention is not limited as long as it is applied to the oral cavity and can stay in the oral cavity for a certain period of time, but for example, an oral spray (including a throat spray agent), a mouse.
  • Oral care products such as wash, mouthwash, liquid dentifrice, kneaded dentin, mouth refresher, oral pasta, gingival massage cream and the like can be mentioned.
  • an oral spray, a mouthwash, a mouthwash, and more preferably an oral spray are preferable.
  • the oral composition of the present invention When applied to the oral cavity, the oral composition of the present invention can extinguish and / or sterilize the oral cavity and can continuously exert a moisturizing effect on the oral mucosa. Therefore, for example, prevention of dry mouth or Suitable for therapeutic use.
  • the usage and volume of the oral composition of the present invention are appropriately set according to the content of each compounding component, the pharmaceutical form of the oral composition, the expected effect, etc., and are, for example, 1 to 1 per day. An appropriate amount may be applied intraorally at a frequency of 6 times.
  • Test Example 1 Oral compositions (oral sprays) having the compositions shown in Tables 1 and 2 were prepared.
  • the obtained oral composition was evaluated for its long-lasting moisturizing effect on the oral mucosa by the following method. First, the edible pig tongue (unsliced) excised as a pseudo-mucosa is lightly moistened with running water and then lightly wiped off. It was allowed to stand until the measured value at Yoshida Co., Ltd.) reached the drying index value (25 or less). Next, the obtained oral composition was placed in a spray container, and about 0.3 ml of the oral composition was spray-applied to a portion slightly from the center of the pig tongue to a portion slightly from the tip, and the temperature was 30 ° C. and the relative humidity was 30%.
  • the moisture value of the pig tongue part to which the oral composition was applied was measured using an oral moisture meter (Oral Moisture Meter Mucus, Yoshida Co., Ltd.) and calculated as follows. According to the formula, the water retention rate (%) 6 hours after application was calculated, and the value rounded off to the first digit was taken as the water retention rate (%) 6 hours after application.
  • Formulation Example 1 An oral composition (oral spray) having the composition shown in Table 3 was prepared.
  • a comparative oral composition in which the hypromellose of Formulation Examples 5 and 6 was changed to purified water was also prepared.
  • the sustainability of the moisturizing effect of these oral compositions was evaluated by the same method as in Test Example 1.
  • the water retention rate after 6 hours of application was significantly higher than that of Comparative Examples 1 to 18.
  • the water retention rate after 6 hours of application was the comparative oral composition of Formulation Examples 5 and 6, and Comparative Examples 1 to 18. Compared with, the sustainability of the moisturizing effect was significantly increased.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une composition pour la cavité buccale, laquelle permet de supprimer les bactéries à l'intérieur de la cavité buccale tout en conférant un effet durable d'hydratation de la muqueuse buccale. Plus spécifiquement, cette composition pour la cavité buccale contient: (A) un sel d'ammonium quaternaire, et (B) une hypromellose.
PCT/JP2021/039363 2020-10-30 2021-10-25 Composition pour la cavité buccale Ceased WO2022092041A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020182428A JP7755923B2 (ja) 2020-10-30 2020-10-30 口腔用組成物
JP2020-182428 2020-10-30

Publications (1)

Publication Number Publication Date
WO2022092041A1 true WO2022092041A1 (fr) 2022-05-05

Family

ID=81382459

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2021/039363 Ceased WO2022092041A1 (fr) 2020-10-30 2021-10-25 Composition pour la cavité buccale

Country Status (3)

Country Link
JP (1) JP7755923B2 (fr)
TW (1) TW202228685A (fr)
WO (1) WO2022092041A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009242349A (ja) * 2008-03-31 2009-10-22 Kobayashi Pharmaceut Co Ltd 口腔乾燥症改善剤
JP2013043869A (ja) * 2011-08-25 2013-03-04 Lion Corp 口腔用軟膏組成物及び口腔バイオフィルム殺菌剤
JP2019006736A (ja) * 2017-06-28 2019-01-17 小林製薬株式会社 医薬組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10251131A (ja) * 1997-03-11 1998-09-22 Sunstar Inc 口腔用組成物
JP5461785B2 (ja) * 2008-03-31 2014-04-02 小林製薬株式会社 繰り返し感染予防用の医薬組成物
JP2018052886A (ja) * 2016-09-29 2018-04-05 小林製薬株式会社 水性製剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009242349A (ja) * 2008-03-31 2009-10-22 Kobayashi Pharmaceut Co Ltd 口腔乾燥症改善剤
JP2013043869A (ja) * 2011-08-25 2013-03-04 Lion Corp 口腔用軟膏組成物及び口腔バイオフィルム殺菌剤
JP2019006736A (ja) * 2017-06-28 2019-01-17 小林製薬株式会社 医薬組成物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KITAGAWA, TETSUTARO ET AL.: "Clinical analysis of outpatients for treatment of mouth dryness", JAPANESE JOURNAL OF GERODONTOLOGY, vol. 24, no. 2, 1 January 2009 (2009-01-01), pages 161 - 162, XP009536556, ISSN: 0914-3866 *
WATANABE, AKIRA: "Xerostomia [my treatment]", JAPANESE MEDICAL JOURNAL, no. 4983, 24 October 2019 (2019-10-24), JP , pages 50, XP009536557, ISSN: 0385-9215 *

Also Published As

Publication number Publication date
JP2022072788A (ja) 2022-05-17
JP7755923B2 (ja) 2025-10-17
TW202228685A (zh) 2022-08-01

Similar Documents

Publication Publication Date Title
JP5548969B2 (ja) 歯磨組成物
JP7431516B2 (ja) 口腔用組成物
JP2012153677A (ja) 口腔用組成物
JP6381912B2 (ja) 口腔用組成物
PT1635852E (pt) ''utilização de composições para reconstituição de unhas para aplicação tópica em onicosquise''
JP7108383B2 (ja) 口腔用組成物
TWI766912B (zh) 水性製劑
JP7359909B2 (ja) 口腔用組成物の製造方法、口腔用組成物の口腔内塗布部との密着性を向上させる方法および口腔用組成物の口腔内塗布部における滞留性を向上させる方法。
JP7455317B2 (ja) 口腔用組成物
JP6903411B2 (ja) 外用組成物
JP7634963B2 (ja) 口腔用組成物
JP7755923B2 (ja) 口腔用組成物
JP2018052887A (ja) 水性製剤
JP2018052886A (ja) 水性製剤
JP6734090B2 (ja) 口腔用組成物
JP7629709B2 (ja) 口腔用組成物
JP7050135B2 (ja) 口腔用又は外用組成物
JP7539829B2 (ja) 口腔用組成物
JP2009242349A (ja) 口腔乾燥症改善剤
JP2022001557A (ja) 口腔粘膜炎又は口腔感染症の痛み抑制剤及びこれを含有する口腔用組成物
JP7789515B2 (ja) 糖化抑制剤
JP2022072786A (ja) 口腔用組成物
JP2009143831A (ja) 口腔用組成物
JP7102107B2 (ja) 水性製剤
JP2026031226A (ja) 口腔用組成物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21886159

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21886159

Country of ref document: EP

Kind code of ref document: A1